JP2023541087A - Ｆｒｚｂタンパク質の「ネトリン様」ドメインに由来するペプチドの治療可能性 - Google Patents

Ｆｒｚｂタンパク質の「ネトリン様」ドメインに由来するペプチドの治療可能性 Download PDF

Info

Publication number
JP2023541087A
JP2023541087A JP2022571252A JP2022571252A JP2023541087A JP 2023541087 A JP2023541087 A JP 2023541087A JP 2022571252 A JP2022571252 A JP 2022571252A JP 2022571252 A JP2022571252 A JP 2022571252A JP 2023541087 A JP2023541087 A JP 2023541087A
Authority
JP
Japan
Prior art keywords
pep16
results
cells
pathway
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541087A5 (https=
Inventor
カイロット，フレデリック
クローデル，マリオン
シャロン，クリストフ
ジョゾ，ジャン－イブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National Polytechnique de Lorraine
Original Assignee
Institut National Polytechnique de Lorraine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National Polytechnique de Lorraine filed Critical Institut National Polytechnique de Lorraine
Publication of JP2023541087A publication Critical patent/JP2023541087A/ja
Publication of JP2023541087A5 publication Critical patent/JP2023541087A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022571252A 2020-05-18 2021-05-18 Ｆｒｚｂタンパク質の「ネトリン様」ドメインに由来するペプチドの治療可能性 Pending JP2023541087A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20315243.4 2020-05-18
EP20315243.4A EP3912991A1 (en) 2020-05-18 2020-05-18 Therapeutic potential of peptides from the "netrin-like" domain of the frzb protein
PCT/EP2021/063109 WO2021233896A1 (en) 2020-05-18 2021-05-18 Therapeutic potential of peptides from the "netrin-like" domain of the frzb protein

Publications (2)

Publication Number Publication Date
JP2023541087A true JP2023541087A (ja) 2023-09-28
JP2023541087A5 JP2023541087A5 (https=) 2024-05-28

Family

ID=71607831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571252A Pending JP2023541087A (ja) 2020-05-18 2021-05-18 Ｆｒｚｂタンパク質の「ネトリン様」ドメインに由来するペプチドの治療可能性

Country Status (6)

Country Link
US (1) US20230183303A1 (https=)
EP (2) EP3912991A1 (https=)
JP (1) JP2023541087A (https=)
CN (1) CN115996944A (https=)
CA (1) CA3178537A1 (https=)
WO (1) WO2021233896A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202401058D0 (en) * 2024-01-26 2024-03-13 Univ London Queen Mary Treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070448A2 (en) * 2004-01-21 2005-08-04 Five Prime Therapeutics, Inc. Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
EP1498133A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma Deutschland GmbH Use of a pak inhibitor for the treatment of a joint disease
WO2015176066A2 (en) * 2014-05-16 2015-11-19 Intermune, Inc. Lpa-associated protein and rna expression
JP5967685B1 (ja) * 2016-01-13 2016-08-10 国立大学法人名古屋大学 軟骨細胞のＷｎｔ／β−カテニンシグナル伝達経路の活性化抑制組成物及び変形性関節症治療用医薬組成物
FR3051192B1 (fr) 2016-05-13 2020-12-25 Univ De Lorraine Methode de purification de proteines recombinantes par affinite basee sur l'activite lectinique du domaine crd d'une galectine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070448A2 (en) * 2004-01-21 2005-08-04 Five Prime Therapeutics, Inc. Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLAUDEL M. ET AL.: "Secreted Frizzled-related proteins (sFRPs) in osteo-articular diseases: much more than simple antago", FEBS J, vol. 286, JPN6025018018, 2019, pages 4832 - 4851, ISSN: 0005587457 *
THYSEN S. ET AL.: "A5.12 SFRPS in cartilage biology: more than just WNT antagonists", ANN RHEUM DIS, vol. vol.73(Suppl 1), JPN6025018017, 2014, pages 67 - 68, ISSN: 0005587456 *
THYSEN S. ET AL.: "Osteogenesis induced by frizzled-related protein (FRZB) is linked to the netrin-like domain", LAB INVEST, vol. 96, JPN6025018019, 2016, pages 570 - 580, ISSN: 0005587455 *

Also Published As

Publication number Publication date
CA3178537A1 (en) 2021-11-25
US20230183303A1 (en) 2023-06-15
EP4153611A1 (en) 2023-03-29
EP3912991A1 (en) 2021-11-24
CN115996944A (zh) 2023-04-21
WO2021233896A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
Li et al. Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis
Blom et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt‐induced signaling protein 1
Zhang et al. Overexpression of MiR‐335‐5p promotes bone formation and regeneration in mice
Zou et al. In vitro study of enhanced osteogenesis induced by HIF‐1α‐transduced bone marrow stem cells
Zhang et al. Hedgehog signaling controls bone homeostasis by regulating osteogenic/adipogenic fate of skeletal stem/progenitor cells in mice
Yu et al. Wnt7b-induced Sox11 functions enhance self-renewal and osteogenic commitment of bone marrow mesenchymal stem cells
Liu et al. Alkaline phosphatase controls lineage switching of mesenchymal stem cells by regulating the LRP6/GSK3β complex in hypophosphatasia
Appelman-Dijkstra et al. From disease to treatment: from rare skeletal disorders to treatments for osteoporosis
Chen et al. Fgf9 regulates bone marrow mesenchymal stem cell fate and bone-fat balance in osteoporosis by PI3K/AKT/Hippo and MEK/ERK signaling
US20190382732A1 (en) Compositions and methods relating to myomixer-promoted muscle cell fusion
Dong et al. ASIC1a-CMPK2-mediated M1 macrophage polarization exacerbates chondrocyte senescence in osteoarthritis through IL-18
CN118649238A (zh) Ddx3x抑制剂在制备治疗人工关节无菌性松动的药物中的应用
Li et al. Cross‐talk between histone and DNA methylation mediates bone loss in hind limb unloading
JP2023541087A (ja) Ｆｒｚｂタンパク質の「ネトリン様」ドメインに由来するペプチドの治療可能性
Mandelin et al. Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation
Zhao et al. MicroRNA-204-5p inhibits the osteogenic differentiation of ankylosing spondylitis fibroblasts by regulating the Notch2 signaling pathway
Zhang et al. Matrix Gla protein suppresses osteoblast senescence and promotes osteogenic differentiation by the PI3K-AKT signaling pathway
Pan et al. Effects of core binding factor α1 or bone morphogenic protein‐2 overexpression on osteoblast/cementoblast‐related gene expressions in NIH3T3 mouse cells and dental follicle cells
Grandi et al. Systemic Factors Affect Bone Health in SMA Type II Patients and a Mouse Model of SMA
US20080242599A1 (en) Compositions and Methods for Increasing Osteoblast Cell Differentiation and Bone Generation
Wang et al. Pathomechanism of LYPD6 enhancing abnormal hyperostosis via Wnt/β-catenin signaling pathway in diffuse idiopathic skeletal hyperostosis
Hu et al. Overactivation of EGFR signaling in skeletal stem/progenitor cells promotes bone formation and repair
US20050239094A1 (en) Compositions and methods for inducing and regulating bone formation
CN113827622B (zh) 奇异变形杆菌外膜囊泡在制备预防或治疗骨溶解性疾病药物中的应用
Tian et al. Endoplasmic reticulum stress and autophagy as potential therapeutic targets in SERPINF1 mutation-induced type VI osteogenesis imperfecta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251028